search
Back to results

An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
MK-0941
Placebo
LANTUS insulin
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female (of non-childbearing potential) between 18 to 70 years of age
  • Diagnosed with Type 2 Diabetes and currently being treated with basal insulin
  • Smokers may participate, but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules

Exclusion Criteria:

  • History of Type 1 diabetes
  • Treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to study start
  • History of severe hypoglycemia
  • Allergic to insulin

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Placebo Comparator

    Arm Label

    MK-0941

    Placebo

    Arm Description

    Outcomes

    Primary Outcome Measures

    Number of Participants Who Experienced an Adverse Event During the Study

    Secondary Outcome Measures

    Number of Participants Who Experienced an Adverse Event - Titration Scheme 1
    In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis in 10-mg q.a.c. increments on Titration Dose [TD] Days 1 to 4 of the Titration Phase 1 of the study.
    Number of Participants Who Experienced an Adverse Event - Titration Scheme 2
    Titration Scheme #2 (Titration Phase, Days 1 to 4) was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration.
    24-Hour Weighted Mean Blood Glucose Levels (mg/dL) by Treatment Group on Day 7
    Measurement of the 24-hour weighted mean blood glucose levels of participants receiving MK-0941 or placebo while on basal insulin on Day 7.
    Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period
    During the Outpatient Treatment Period, participants were followed for an additional 2 weeks while at home.

    Full Information

    First Posted
    August 2, 2007
    Last Updated
    June 19, 2015
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00511472
    Brief Title
    An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
    Official Title
    A Multicenter, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 on Postprandial Plasma Glucose Concentrations After Daily Administration MK-0941 Before Each Meal (q.a.c) in Subjects With Type 2 Diabetes Being Treated With Basal Insulin
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2007 (undefined)
    Primary Completion Date
    April 2008 (Actual)
    Study Completion Date
    April 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    5. Study Description

    Brief Summary
    A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    70 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    MK-0941
    Arm Type
    Experimental
    Arm Title
    Placebo
    Arm Type
    Placebo Comparator
    Intervention Type
    Drug
    Intervention Name(s)
    MK-0941
    Intervention Description
    In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments. Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2.
    Intervention Type
    Drug
    Intervention Name(s)
    Placebo
    Intervention Description
    10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
    Intervention Type
    Drug
    Intervention Name(s)
    LANTUS insulin
    Other Intervention Name(s)
    LANTUS
    Intervention Description
    LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
    Primary Outcome Measure Information:
    Title
    Number of Participants Who Experienced an Adverse Event During the Study
    Time Frame
    39 days
    Secondary Outcome Measure Information:
    Title
    Number of Participants Who Experienced an Adverse Event - Titration Scheme 1
    Description
    In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis in 10-mg q.a.c. increments on Titration Dose [TD] Days 1 to 4 of the Titration Phase 1 of the study.
    Time Frame
    25 days
    Title
    Number of Participants Who Experienced an Adverse Event - Titration Scheme 2
    Description
    Titration Scheme #2 (Titration Phase, Days 1 to 4) was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration.
    Time Frame
    25 days
    Title
    24-Hour Weighted Mean Blood Glucose Levels (mg/dL) by Treatment Group on Day 7
    Description
    Measurement of the 24-hour weighted mean blood glucose levels of participants receiving MK-0941 or placebo while on basal insulin on Day 7.
    Time Frame
    24 hours
    Title
    Number of Participants Who Experienced an Adverse Event During the Outpatient Treatment Period
    Description
    During the Outpatient Treatment Period, participants were followed for an additional 2 weeks while at home.
    Time Frame
    Outpatient Days 1 to 14

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    70 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Male or female (of non-childbearing potential) between 18 to 70 years of age Diagnosed with Type 2 Diabetes and currently being treated with basal insulin Smokers may participate, but they are limited to 10 cigarettes per day while at the clinic and must follow clinic smoking rules Exclusion Criteria: History of Type 1 diabetes Treated with peroxisome proliferator-activated receptor (PPAR) agonists within 12 weeks prior to study start History of severe hypoglycemia Allergic to insulin
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)

    We'll reach out to this number within 24 hrs